Psychedelic Research Expands In Australia With Palliative Care Partnership & New MDMA Analog Portfolio
Psyence Partners with iNGENū for Palliative Care Clinical Trial
EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility
In light of the latest news regarding the DEA’s telehealth regulations and the
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.
Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock
FSD Pharma Inc. (NASDAQ: HUGE) has renewed a service agreement with shareholder intelligence services provider ShareIntel LLC to assist in ongoing
COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression
COMPASS Pathways' (NASDAQ: CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TR
Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court
Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey.
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial
These Companies Team Up To Try To Bring Psilocybin Microdosing Capsules To Australasia
Red Light Holland Corp. (OTCQB: TRUFF) (CSE:TRIP) (FSE:4YX) has signed a distribution agreement with MW Pharma Limited t/a NUBU Pharmaceuticals, to explore the possibility of legal import and distribution of Red Light Holland's psilocybin microdosing capsules to
MindMed Reports Full-Year 2022 Financial Results, Highlighting Anxiety & Autism Studies
Clinical-stage biopharma company Mind Medicine (MindMed), Inc. (NASDAQ: MNMD) shared its financial results for the full year ended Dec. 31, 2022.
Numbers show solid stability:
Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic
The next-generation psychedelics R&D business is up and running, as BetterLife Pharma Inc.